Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jonesboro, Arkansas


Purpose:

In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.


Criteria:

Inclusion Criteria: - Confirmed active head lice infestation Exclusion Criteria: - Allergy to pediculicides or hair care products - Scalp conditions other than head lice - Previous head lice treatment within the past 4 weeks - Current antibiotic treatment


Study is Available At:


Original ID:

MALG-0813


NCT ID:

NCT00752973


Secondary ID:


Study Acronym:


Brief Title:

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice


Official Title:

Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis


Overall Status:

Completed


Study Phase:

Phase 2/Phase 3


Genders:

Both


Minimum Age:

6 Months


Maximum Age:

24 Months


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Taro Pharmaceuticals USA


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Non-Randomized, Endpoint Classificatio


Number of Arms:

1


Number of Groups:

0


Total Enrollment:

30


Enrollment Type:

Anticipated


Study Dates

Start Date:September 2008
Completion Date:January 2012
Completion Type:Actual
Primary Completion Date:December 2011
Primary Completion Type:Actual
Verification Date:November 2013
Last Changed Date:December 19, 2013
First Received Date:September 15, 2008

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Cure of head lice 14 days after last treatment
Time Frame:2-3 weeks
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Local tolerability
Time Frame:2-3 weeks
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Clinical evidence of cholinesterase inhibition
Time Frame:1 day
Safety Issues:True
Outcome Type:Primary Outcome
Measure:Change in cholinesterase level
Time Frame:1 day
Safety Issues:True

Study Interventions

Intervention Type:Drug
Name:MALG (malathion) Treatment
Description:MALG applied for 30 minutes
Arm Name:Treatment arm
Other Name:Novel malathion formulation

Study Arms

Study Arm Type:Experimental
Arm Name:Treatment arm
Description:MALG treatment

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Taro Pharmaceuticals USA

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Meinking TL, Vicaria M, Eyerdam DH, Villar ME, Reyna S, Suarez G. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Crème Rinse (1% permethrin) used as labeled, for the treatment of head lice. Pediatr Dermatol. 2007 Jul-Aug;24(4):405-11.
PMID:17845167

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.